Beylot-Barry, Marie
Mahé, Emmanuel
Rolland, Carole
de la Bretèque, Maud Amy
Eychenne, Claire
Charles, Julie
Payen, Catherine
Machet, Laurent
Vermorel, Céline
Foote, Alison
Roques, Christian
Bosson, Jean-Luc http://orcid.org/0000-0003-0967-6026
Funding for this research was provided by:
afreth
Article History
Received: 4 July 2021
Revised: 9 March 2022
Accepted: 11 March 2022
First Online: 26 March 2022
Declarations
:
: The study was approved by the French Ethics committee “Sud-Ouest et Outre Mer III” on 07/01/2014. N° ID RCB: 2013-A01369-39. This clinical trial complies with the current laws for biomedical research involving humans in France.
: M. Beylot-Barry is a consultant for Abbvie, Celgene, Janssen-Cilag, Lilly, Novartis, Medac, and UCB. E. Mahé has paid activities as a consultant, advisor, or speaker for AbbVie, Janssen-Cilag, Celgene, Leo Pharma, Amgen, Lilly, and Novartis. None of the other authors has a conflict of interest to declare.